Content area


Akut induceret diabetes mellitus hos en patient i behandling for metastaserende malignt melanom

Malignt melanom. (Foto: Georg Authried, Dermatologisk Afdeling, Odense Universitetshospital).
Line Bisgaard Jørgensen & Knud Yderstræde Endokrinologisk Afdeling M, Odense Universitetshospital Ugeskr Læger 2017;179:V03170188
Ugeskr Læger 2017;179:V03170188
Blad nummer: 
Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma
Immune checkpoint inhibitors have improved survival rate in patients with advanced melanoma, but also have the potential to induce several adverse events. We report on a 63-year-old woman who had advanced melanoma and was admitted with diabetic ketoacidosis, which had occurred upon treatment with ipilimumab. On admission, the C-peptide level was low, and the HbA1c concentration was 50 mmol/l indicating a rapid onset of the disease. The patient had also been diagnosed with thyroiditis. Diabetes mellitus is a rare and serious side effect of treatment with ipilimumab, and we recommend being aware of this due to the rapid course.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Pedram Kazemi-Esfarjani | 18/01
2 kommentarer
af Johan Ludvig Reventlow | 18/01
1 Kommentar
af Claus Manniche | 18/01
1 Kommentar
af Bjarne Skjødt Hjaltalin | 18/01
1 Kommentar
af Yngve Lund | 17/01
13 kommentarer
af Jens Meyer Svendsen | 16/01
1 Kommentar
af Claus Rasmussen | 16/01
3 kommentarer
af Thomas Eric Olesen | 15/01
2 kommentarer